Nevertheless, in CRY1 CpG2 and CpG5 and in CLOCK CpG1 increasing levels of methylation tended to be associated with lower odds of breast cancer (OR 0.88; 95% CI 0.76–1.02, OR 0.84; 95% CI 0.74–0.96, and OR 0.80; 95% CI: 0.68–0.94, respectively) (Fig. 1). Here, CRY1 is linked to breast carcinoma.